We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

182 hedge funds and large institutions have $1.83B invested in Aerie Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $33.7M | Put options by funds: $18M

66% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 47

58% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 19

6% more funds holding

Funds holding: 172 → 182 (+10)

1% more capital invested

Capital invested by funds: $1.81B → $1.83B (+$16.8M)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
182
Holders Change
+10
Holders Change %
+5.81%
% of All Funds
4.54%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.17%
New
30
Increased
78
Reduced
47
Closed
19
Calls
$33.7M
Puts
$18M
Net Calls
+$15.8M
Net Calls Change
+$17.9M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$84.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$46M
3
PHS
PFM Health Sciences
California
+$36.3M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$15.2M
5
WRF
Waddell & Reed Financial
Kansas
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$20.5M
3
DM
Deerfield Management
New York
-$17.9M
4
Deutsche Bank
Deutsche Bank
Germany
-$17.6M
5
BC
Broadfin Capital
New York
-$13.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
76
Weiss Multi-Strategy Advisers
New York
$2.43M – – –
GPCM
77
Granite Point Capital Management
Massachusetts
$2.42M -$663K -12,159 -20%
HI
78
Handelsinvest Investeringsforvaltning
Denmark
$2.2M – – –
AI
79
Axiom Investors
Connecticut
$2.09M +$2.35M +43,062 New
LCM
80
Legato Capital Management
California
$1.99M +$18.6K +341 +0.8%
UBS AM
81
UBS AM
Illinois
$1.98M +$1.28M +23,522 +137%
UBS Group
82
UBS Group
Switzerland
$1.94M +$2.1M +38,438 +2,651%
Royal Bank of Canada
83
Royal Bank of Canada
Ontario, Canada
$1.94M -$2.05M -37,643 -49%
New York State Common Retirement Fund
84
New York State Common Retirement Fund
New York
$1.83M -$686K -12,573 -25%
PIM
85
Platinum Investment Management
Australia
$1.83M -$267K -4,900 -12%
RhumbLine Advisers
86
RhumbLine Advisers
Massachusetts
$1.78M +$94.5K +1,732 +5%
AA
87
ALPS Advisors
Colorado
$1.74M +$210K +3,856 +12%
AQR Capital Management
88
AQR Capital Management
Connecticut
$1.71M +$24.9K +457 +1%
HCMT
89
Highland Capital Management (Texas)
Texas
$1.7M +$1.91M +35,000 New
PIM
90
Partner Investment Management
California
$1.54M -$43.3K -794 -2%
Macquarie Group
91
Macquarie Group
Australia
$1.5M +$1.05M +19,160 +165%
BCA
92
Benchmark Capital Advisors
New York
$1.43M +$873K +16,000 +119%
Wells Fargo
93
Wells Fargo
California
$1.31M +$124K +2,266 +9%
CIP
94
Chartwell Investment Partners
Pennsylvania
$1.24M +$43.2K +791 +3%
Neuberger Berman Group
95
Neuberger Berman Group
New York
$1.22M +$682K +12,500 +100%
Manulife (Manufacturers Life Insurance)
96
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.21M +$76.2K +1,397 +6%
HCM
97
Harvey Capital Management
Florida
$1.21M -$104K -1,900 -7%
American Century Companies
98
American Century Companies
Missouri
$1.18M +$12.4K +228 +0.9%
State of Wisconsin Investment Board
99
State of Wisconsin Investment Board
Wisconsin
$1.12M – – –
ProShare Advisors
100
ProShare Advisors
Maryland
$1.1M +$112K +2,061 +10%
2 3
4
5 6

AERI Hedge Fund Activity: Q3 2017 in Review

182 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2017, worth a combined $1.83B — up 0.93% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AERI positions and 19 closed out — a net gain of 11 holders — while 78 added to existing stakes and 47 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $84.7M. The largest seller was OrbiMed, cutting an estimated $21.5M.

  • 182 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2017, up from 172 in Q2 2017.
  • Funds reported $1.83B of Aerie Pharmaceuticals stock for Q3 2017, up 0.93% quarter-over-quarter.
  • 30 funds opened new Aerie Pharmaceuticals positions in Q3 2017 and 19 closed out, a net change of +11 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2017 was Wellington Management Group, an estimated $84.7M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2017 was OrbiMed, an estimated $21.5M sold.

Based on aggregated 13F filings for Q3 2017.